Analyst Group: Analyst Group Comment on STENOCAREs acquisition of CannGros ApS
On November 17th, STENOCARE A/S (“STENOCARE” or “the Company”) announced that the Company has entered into a share purchase agreement with DanCann Pharma A/S (“DanCann”) to acquire 100% of the shares in CannGros ApS (“CannGros”), a wholly owned subsidiary of DanCann. Through the agreement, Stenocare adds a new product category to its portfolio and becomes the market leading medical cannabis supplier in Denmark. The transaction is executed as a share exchange, where 5,000,000 new Stenocare shares will be issued to DanCann.
In conclusion, Analyst Group considers the acquisition of CannGros to be both strategically and financially compelling for STENOCARE. The transaction broadens the Company’s product portfolio from four to nine treatments, strengthens its presence in the fast-growing flower segment, and enables STENOCARE to address a wider range of patient needs through complementary oil- and flower-based formulations. With CannGros expected to contribute DKK 4–6m in revenue in 2026, equivalent to a 71–106% uplift versus STENOCARE’s current LTM sales, the deal provides meaningful top-line expansion while leveraging existing operational infrastructure, thereby generating cost synergies. Moreover, the acquisition is executed at a lower sales multiple than STENOCARE’s own valuation, which in combination with the expected synergies creates an attractive purchase price according to Analyst Group. Combined with CannGros’ strong market position, recurring demand profile, and STENOCARE’s recent progress toward EBITDA break-even, the acquisition is expected to support improved earnings, strengthen cash flow, and reinforce the Company’s path toward reaching and potentially exceeding its 2026 profitability target.
Read Analyst Group’s comment here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Stenocare. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.